Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 11/20 | 0.46 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NEK9 | Q8TD19 | 1/20 | 0.39 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747140 | 0.86 | PDPK1 (0.43) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4747764 | 0.79 | PDPK1 (0.42) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4745763 | 0.79 | SPIN1 (0.44) | PDPK1SPIN1 | |
| SCHEMBL4747807 | 0.77 | PDPK1 (0.44) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL24355432 | 0.72 | PDPK1 (0.57) | PDPK1LMNAGLAPOLBGAA | |
| SCHEMBL29756065 | 0.72 | PDPK1 (0.57) | PDPK1LMNAGLAPOLBGAA | |
| SCHEMBL26069539 | 0.69 | PDPK1 (0.55) | PDPK1LMNAGLAPOLBGAA | |
| SCHEMBL24355412 | 0.69 | GAK (0.56) | PDPK1 | |
| SCHEMBL4747754 | 0.69 | PDPK1 (0.68) | PDPK1LMNAGLAPOLBGAA | |
| SCHEMBL4929414 | 0.68 | PDPK1 (0.58) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PDPK1 6/4885SPIN1 3838/4885TYK2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.